Mitigating the harm caused by Pseudomonas aeruginosa in Cystic Fibrosis

QR Code

Mitigating the harm caused by Pseudomonas aeruginosa in Cystic Fibrosis

Cystic fibrosis (CF) affects up to 100,000 people worldwide. Defects in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene cause abnormally viscid secretions at epithelial surfaces. In the lungs the abnormal secretions reduce clearance of both pathogens and sputum, predisposing to recurrent lun...

Full description

Bibliographic Details
Main Author:	Palser, Sally C.
Format:	Thesis (University of Nottingham only)
Language:	English
Published:	2024
Subjects:	Cystic Fibrosis; Pseudomonas aeruginosa; Ototoxicity; Hearing loss; Patient and public involvement
Online Access:	https://eprints.nottingham.ac.uk/77908/

Similar Items

Surviving and thriving in the cystic fibrosis lung: contribution of an arginine specific aminopeptidase to sustained infection by Pseudomonas aeruginosa
by: Spencer, Daniella Lucy
Published: (2019)

Lectin-mediated biofilm maturation, quorum sensing and Pseudomonas aeruginosa infections in cystic fibrosis
by: Crusz, S.A.
Published: (2009)

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
by: Langton Hewer, Simon C., et al.
Published: (2014)

Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

Working with the patient and clinical community to deliver clinical research in cystic fibrosis. James Lind CF Phase II
by: Smith, S.J., et al.
Published: (2018)

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

An ex vivo lung model to study bronchioles infected with Pseudomonas aeruginosa biofilms
by: Harrison, Freya, et al.
Published: (2016)

An evaluation of the High Frequency Digit Triplet Test as a screening tool for early detection of hearing loss in individuals with Cystic Fibrosis. Protocol v2.1.
by: Smyth, Alan R., et al.
Published: (2016)

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients
by: Elborn, J. Stuart, et al.
Published: (2015)

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients
by: Flume, Patrick, et al.
Published: (2016)

Biosurfactant Production by Pseudomonas Aeruginosa 181
by: Yassin Al-Araji, Laith Issa
Published: (2004)

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and health care providers
by: Rowbotham, Nicola J., et al.
Published: (2017)

Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium
by: Freschi, Luca, et al.
Published: (2015)

In vitro study of effects of antibiotics on Pseudomonas aeruginosa biofilm formation
by: Jeevajothi Nathan, Priadarssini
Published: (2017)

Production and characterization of biosurfactant by isolated Pseudomonas aeruginosa RS6 strain
by: Nordin, Nordiyana
Published: (2016)

Delayed publications of clinical trials in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2011)

Glutamine supplementation in cystic fibrosis: a randomized placebo-controlled trial
by: Forrester, Doug L., et al.
Published: (2015)

Characterization of an Organic Solvent-Tolerant Protease from Pseudomonas Aeruginosa Strain K
by: Lee, Poh Geok
Published: (2003)

Cystic Fibrosis isolates of Pseudomonas aeruginosa retain iron-regulated antimicrobial activity against Staphylococcus aureus through the action of multiple alkylquinolones
by: Nguyen, Angela T., et al.
Published: (2016)

Production of biosurfactant from biodiesel side-stream glycerine by Pseudomonas aeruginosa RS6
by: Baskaran, Shobanah Menon
Published: (2020)

Role of lectin receptors in recognition of Pseudomonas aeruginosa biofilms
by: Almuhanna, Yasir Saleh I
Published: (2021)

SadB is a Pseudomonas aeruginosa global regulator
by: Papangeli, Maria
Published: (2022)

Prevalence of metallo-Beta-lactamase producing Pseudomonas aeruginosa in a tertiary care at Hospital Kuala Lumpur, Malaysia
by: Idris, Siti Nur Atiqah
Published: (2016)

Search for Pseudomonas aeruginosa immune-modulatory but non-inducing agents
by: Jadhav, Gopal P.
Published: (2008)

European Cystic Fibrosis Society standards of care: best practice guidelines
by: Smyth, Alan R., et al.
Published: (2014)

Xbox Kinect™ represents high intensity exercise for adults with cystic fibrosis
by: Holmes, H., et al.
Published: (2013)

Understanding chronic inflammatory diseases in the human lung: the cystic fibrosis and idiopathic pulmonary fibrosis paradigms
by: Liu, Yi-Chia
Published: (2014)

Use of a primary epithelial cell screening tool to investigate phage therapy in cystic fibrosis
by: Trend, S., et al.
Published: (2018)

Antimicrobial and anti-quorum sensing activties of javanese turmeric (Curcuma xanthorrhiza Roxb.) ethanolic extract against Pseudomonas aeruginosa
by: Othman, Ahmad Fiqri Mustaqim
Published: (2018)

Airway infection and Pseudomonas aeruginosa in bronchiectasis (cystic fibrosis and non-cystic fibrosis bronchiectasis)
by: Webb, Karmel
Published: (2022)

Understanding the contribution of Resistance-Nodulation-Division family efflux pumps to the lifestyle of Pseudomonas aeruginosa
by: Scales, Danielle
Published: (2023)

Metabolic functions of the Pseudomonas aeruginosa aminoglycoside resistance gene, aph
by: Aksoy, Cemile Selin
Published: (2024)

Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis.
by: Thomson, E., et al.
Published: (2010)

Development of a transition readiness scale for young adults with cystic fibrosis: face and content validity
by: Dudman, Lauren, et al.
Published: (2011)

Early respiratory bacterial detection and anti-staphylococcal antibiotic prophylaxis in young children with cystic fibrosis
by: Hurley, Matthew, et al.
Published: (2017)

Understanding the Costs of Care for Cystic Fibrosis: an Analysis by Age and Health State
by: Van Gool, K., et al.
Published: (2013)

Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
by: Norman, Richard, et al.
Published: (2012)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison
by: Prayle, A.P., et al.
Published: (2015)

Synthesis and biological evaluation of novel PqsR antagonists to combat Pseudomonas aeruginosa infections
by: Mashabi, Alaa
Published: (2021)

Prevention of treatment related adverse effects in cystic fibrosis
by: Jain, Kamini
Published: (2018)